Safety and effectiveness of secukinumab in skin and joint conditions in Korea
Observes secukinumab use in people with hidradenitis suppurativa, childhood psoriasis, or juvenile arthritis.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
- Status
- Recruiting
- People taking part
- 76 people, planned
- Started
- 22 Dec 2025
- Expected to end
- 15 Jun 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- Secukinumab
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe hidradenitis suppurativa, and children and teens aged 6 to 18 with moderate to severe plaque psoriasis or certain types of juvenile idiopathic arthritis. All are receiving or will receive Cosentyx.
- Age
- 6 to 100 years. Hidradenitis suppurativa: 18 years and older. Plaque psoriasis and juvenile idiopathic arthritis: 6 to 18 years.
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe hidradenitis suppurativa (adults) or moderate to severe plaque psoriasis (ages 6 to 18). For juvenile idiopathic arthritis: enthesitis related arthritis or juvenile psoriatic arthritis (ages 6 to 18).
- Earlier treatment
- People must be receiving Cosentyx or be about to receive it, within its approved use.
Main reasons for not taking part
- People for whom Cosentyx is contraindicated under the national prescribing information
- People taking part in other interventional clinical trials
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Hidradenitis suppurativa:
- Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication
- Patients who have agreed to participate in study (written informed consent); Pediatric plaque psoriasis:
- Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication
- Patients with patient or guardian consent to participate in study (written informed consent); Juvenile idiopathic arthritis:
- Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication
- Patients with patient or guardian consent to participate in study (written informed consent)
Who cannot take part
- Patients who are contraindicated according to national prescribing information
- Patients participating in other interventional clinical trials
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 100 years old?
Where in South Korea
- Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
The 3 groups in the trial
- Secukinumab - HS
Participants with Hidradenitis Supurativa who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.
Treatment: Secukinumab
- Secukinumab - Pediatric plaque psoriasis
Participants with pediatric plaque psoriasis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.
Treatment: Secukinumab
- Secukinumab - JIA
Participants with juvenile idiopathic arthritis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.
Treatment: Secukinumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study
- Plain-language title
- Safety and effectiveness of secukinumab in skin and joint conditions in KoreaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07243782, who can take part
- Record updated
- 5 March 2026